Alcuni dati sperimentali indicano che i recettori del GLP-1 siano espressi nelle cellule stellate epatiche le cellule che mediano la fibrosi e che la loro attivazione possa interferire direttamente con i meccanismi cellulari della fibrogenesi
Find support and motivation from our community in our Coaching Hub
We have been burned by diet culture, misinformation, sketchy supplements that dont do anything or trend-diets like Keto, Vegan, and anything else forcing you to ban delicious foods

Executive Vice President & President, Lilly Cardiometabolic Health, Eli Lilly and Company Why this matters 1 Triple agonist = next-gen metabolic therapy Mimics GLP-1, GIP, and glucagon multi-pathway metabolic control 2 Diabetes + obesity convergence Simultaneous A1C + weight control = major unmet need solved 3 Competitive landscape shift Raises the bar vs GLP-1 mono & dual incretin therapies 4 No plateau signal is critical Suggests longer-term sustained efficacy Safety profile (expected class effects) Nausea, diarrhea, vomiting (dose-escalation phase) Discontinuation rates relatively low (25%) My takeaway 1 Metabolic disease treatment is entering multi-hormone era 2 Obesity + diabetes becoming one therapeutic category 3 Efficacy approaching bariatric-level outcomes 4 Sets new benchmark for Novo Nordisk and competitors Bottom line: Retatrutide isnt just competing Its redefining how we treat metabolic disease at the systems level #Diabetes #Obesity #GLP1 #Biotech #ClinicalTrials #Pharma #Innovation To view or add a comment, sign in 2,744 followers

Which Works Better for PCOS: Final Answer Based on the comparisons above, both medications offer distinct advantages for managing PCOS
The body is able to produce glutathione itself, but in your diet as an athlete it is often difficult to accurately measure this increased need